Psoriatic Arthritis

At week 52, 58.5% of patients continuing risankizumab treatment and 55.7% of patients who switched to risankizumab at week 24 achieved ACR20.

Adam Dore, DO, discusses the recent developments in treating psoriatic arthritis and his predictions for the advancement of care in the upcoming year.

Etanercept was effective at 6 months of follow-up and remained so at 12 months, with low rates of adverse events.

Serum levels of BD-2 at baseline were shown to be significantly linked with subsequent clinical response in patients with psoriatic arthritis.

Celastrol may regulate core target proteins to alleviate the inflammatory response.

Guselkumab was able to provide minimal disease activity improvements from baseline through week 48 in adult patients with psoriatic arthritis.

Patients with unrestful sleep had significantly reduced health-related quality of life and significantly more depressive symptoms.

While most patients were interested in an online wellness program for managing their psoriatic arthritis, barriers, such as cost and fatigue, hindered their initiation of lifestyle adaptations.

More than 90% of respondents reported being “somewhat likely” or “very likely” to speak with an online coach ≥2 per week or spend 1 – 2 hours per week learning about lifestyle behaviors if given the opportunity.

A pair of studies presented at EULAR 2023 offer perspective on the potential for postpartum depression as well as symptoms of depression and anxiety during pregnancy among women with rheumatic disease.

Over a 3-year period, patients treated with upadacitinib reported greater disease improvements and a greater mean change from baseline when compared with those receiving adalimumab.

An analysis of data from the phase 4 MOSAIC trail is providing clinicians with a greater understanding of the effects of apremilast in people with uncontrolled psoriatic arthritis.

An analysis of 100 week data from the KEEPsAKE 1 and 2 trials presented at EULAR 2023 offers insight into the long-term effects of risankizumab use in people with psoriatic arthritis.

New data from EULAR 2023 offers a comparison of the levels of vascular inflammation among patients with psoriatic arthritis relative to healthy controls.

Data from the BE VITAL OLE study, which included patients from the BE COMPLETE and BE OPTIMAL studies, suggests the benefits of bimekizumab in patients with psoriatic arthritis with inadequate response or intolerance to TNF inhibitors were sustained for up to 52 weeis.

Janssen's efforts are accompanied by extensive data generation in patients of color and the creation of a diverse workforce.

Janssen aims to address health inequities and promote culturally competent care.

The disparities compelled them to launch Determi-Nation, which utilizes healthcare providers, advocates, and patients within the psoriatic disease community to co-create solutions that address the observed inequities.

Patients with higher platelet or neutrophil counts or platelet/lymphocyte ratios and systemic immune/inflammation index scores were more resistant to conventional systemic agents.

An analysis of patient-reported outcomes data from more than 15,000 people with rheumatic disease sheds light on the apparent differences in impact on quality of life between psoriatic arthritis and rheumatoid arthritis.

The analyses emphasized the early and sustained resolution of enthesitis through 52 weeks with both adalimumab and secukinumab.

Leveraging data from the 2020 UPLIFT survey, investigators offer an overview of the quality of life and treatment satisfaction among people with psoriasis and psoriatic arthritis in the US.

At the 2-year mark after methotrexate initiation, 71% of patients with psoriatic arthritis and 76% of patients with rheumatoid arthritis remained on methotrexate.

Sustained low disease activity/remission was associated with functional and health-related quality of life improvements.